Drugs / GIGA-2339
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07024641 | Nov 2024 → Nov 2028 expected | chronic hepatitis B virus infection | GigaGen, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-19 | Grifols Therapeutics LLC | GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus grifols.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIGA-2339 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024641 ↗ |
| Route | Intravenous | “Administered by intravenous infusion” NCT07024641 ↗ |